Altimmune reports positive results in weight-loss drug trial

Multinational biopharmaceutical company Altimmune (ALT) reports positive results in Phase 2 trials for its weight-loss drug, pemvidutide.

Yahoo Finance Health Reporter Anjalee Khemlani explains the results of the trial, including lean mass loss figures recorded from participants.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Luke Carberry Mogan.

Video transcript

Meanwhile, the race for more obesity drugs is continuing.

There's a smaller company called out to Boon that is trending today as they have some developments on that front.

They do.

They have phase two results, talking about their G LP one drug, which they previously said had about a 15% total weight loss after 48 weeks.

But the good news and the reason why they're up is that they seem to have solved one of the biggest concerns, which is lean mass loss 22% compared to the average of all other incretins, which is what G LP ones belong to, which is about 40%.

And the fat loss is 78% of that.

So that is the reason behind that.

This is getting to be part of that market where we talk about differentiation.

How do these other companies stand up to these market dominators and what makes them different?

No more Ozempic face and no more, that's Yep, yep.

And isn't that what we're talking?

We're talking lean muscle mass going away